Saturday 17 October 2026 Export CRBP’s income statement to Excel — free account

Corbus Pharmaceuticals Holdings, Inc.

In the quarter to June 2026, EPS fell 25.7% and free cash flow fell 78.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

4.52 0.19 +4.39%

Follow CRBP

Alert me

Market cap: $83.8M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: —
F-score: 3/9
Altman Z: −4.15
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.13

Total sells 0.97

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	1	—	1	—	—
Sell	—	1	—	5	1	—	—	3	—	2	1	—

Insider Ownership 10.55%

Capital & Financial Ratios $m

Market Cap 83.75

Revenue 1.54

Net Income (101.90)

Free Cash Flow (86.69)

Net Debt (117.94)

Current Ratio 5.71

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.33)

P/S ratio 56.97

P/B ratio 0.86

Past 5Y EPS Growth —

This Y EPS Growth 7.89%

Next Y EPS Growth (1.46%)

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 1.30%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 37.84%

10-year low 10-year high

P/B against its own 10 years 16.86%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	21	149	164	118
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	24	153	167	123

	2023	2024	2025	Q'26
Payables	3	5	2	5
ST’ Debt	16	—	—	—
Other	0	—	—	—
	32	12	21	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	(14.34%)	(43.24%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	32.29%	26.65%	64.74%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’21	1	0	0	—	1
’20	2	0	1	1	4
’19	2	29	3	3	36
’18	1	1	1	2	5
’17	1	0	1	0	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(30)	—	—	—
’25	(16)	(17)	(16)	(16)	(64)
’24	(8)	(9)	(14)	(11)	(42)
’23	(15)	(8)	(7)	(6)	(36)
’22	(11)	(12)	(7)	(7)	(38)
’21	(22)	(18)	1	(10)	(48)
’20	(28)	(27)	(27)	(18)	(100)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(26)	(30)	—	—	—
’25	(16)	(17)	(16)	(16)	(64)
’24	(8)	(9)	(14)	(11)	(42)
’23	(15)	(8)	(7)	(6)	(36)
’22	(11)	(12)	(7)	(7)	(38)
’21	(22)	(18)	1	(10)	(48)
’20	(28)	(27)	(27)	(18)	(100)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.23)	(1.81)	—	—	—
’25	(1.39)	(1.44)	(1.90)	(1.25)	(5.90)
’24	(0.83)	(0.90)	(1.15)	(0.78)	(3.68)
’23	(4.24)	(2.05)	(2.27)	(1.81)	(10.31)
’22	(2.40)	(3.30)	(2.10)	(2.61)	(10.15)
’21	(4.20)	(4.50)	(0.60)	(2.40)	(11.11)
’20	(12.91)	(15.62)	(12.91)	(3.00)	(42.64)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	30.30	159.00	135.00	125.40	27.30	17.70	3.00	2.11	5.67	4.64	Analyst estimates 2026–2028 Powerpack
	High	323.40	315.00	298.65	273.30	293.40	120.00	20.10	13.17	61.90	20.56
People
People	Employees	25	47	77	141	76	41	33	19	28	36
	Revenue/emp, $m	0.08	0.05	0.06	0.26	0.05	0.02	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	2	2	5	36	4	1	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	0.00	—	—	—
	EBT	(20)	(32)	(56)	(71)	(111)	(46)	(42)	(45)	(40)	(79)
	EBT margin, %	(1,046.29)	(1,328.65)	(1,154.47)	(197.69)	(2,826.10)	(5,176.41)	0.00	0.00	0.00	0.00
	Net income	(20)	(32)	(56)	(71)	(111)	(46)	(42)	(45)	(40)	(79)
	Depreciation	0	0	0	1	2	3	2	1	(2)	(1)
Per share, $
Per share, $	Revenue	1.40	1.46	2.54	16.99	1.51	0.22	0.00	0.00	0.00	0.00
	Earnings	(14.71)	(19.52)	(29.43)	(33.63)	(42.64)	(11.11)	(10.15)	(10.31)	(3.68)	(5.90)
	Cash flow	(9.91)	(16.64)	(15.84)	(21.49)	(38.31)	(11.77)	(9.00)	(8.34)	(3.83)	(4.84)
	Capex	(0.26)	(0.42)	(1.21)	(1.29)	(0.19)	(0.01)	0.00	0.00	0.00	0.00
	Free cash flow	(10.16)	(17.06)	(17.05)	(22.78)	(38.50)	(11.77)	(9.00)	(8.34)	(3.83)	(4.84)
	Book value	6.51	34.58	14.50	2.89	17.40	16.88	7.91	(1.60)	13.05	11.08
	Shares, m	1	2	2	2	3	4	4	4	11	13
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	P/S	181.67	163.31	68.96	9.64	24.78	49.14	—	—	—	—
	P/B	38.94	6.90	12.08	56.60	2.16	1.10	—	—	—	—
	EV/Sales	174.01	137.84	60.43	9.01	7.75	(1.73)	—	—	—	—
	EV/FCF	(23.89)	(11.80)	(9.00)	(6.72)	(0.30)	0.06	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(14)	(28)	(30)	(46)	(100)	(48)	(38)	(36)	(42)	(64)
	Capex	0	(1)	(2)	(3)	0	0	0	—	—	0
	Free cash flow	(14)	(29)	(32)	(48)	(100)	(48)	(38)	(36)	(42)	(64)
Balance, $m
Balance, $m	Working capital	9	57	26	3	60	83	48	(8)	141	146
	Total debt	0	0	0	9	19	19	19	16	—	—
	Net debt	(15)	(62)	(41)	(23)	(67)	(78)	(40)	(5)	(149)	(164)
	Shareholders’ equity	9	58	28	6	45	69	33	(7)	142	148
Returns, %
Returns, %	ROA	(130.02)	(76.41)	(97.70)	(148.66)	(146.95)	(43.46)	(48.66)	(94.32)	(43.67)	(48.47)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(223.40)	(97.21)	(130.52)	(424.29)	(432.68)	(79.80)	(82.95)	(341.99)	(59.34)	(54.18)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2021 · latest quarter Sep 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RLYB Rallybio Corporation	$89.1M	2.0×	— (loss-making)	0.00%	n/m	+648.02% (above 0%: growing)	100.00%	0.00%	Compare
OKUR OnKure Therapeutics, Inc.	$86.3M	— (loss-making)	—	—	n/m	+22.05% (above 0%: growing)	0.00%	0.00%	Compare
KZIA Novogen Limited	$84.6M	— (loss-making)	— (loss-making)	—	−32.67% (below 0%: shrinking)	−51.71% (below 0%: shrinking)	0.00%	0.00%	Compare
AARD Aardvark Therapeutics, Inc.	$84.5M	— (loss-making)	—	—	n/m	−77.14% (below 0%: shrinking)	—	0.00%	Compare
CRBP Corbus Pharmaceuticals Holdings, Inc.	$83.8M	— (loss-making)	— (loss-making)	−92.09% (below 0%: shrinking)	n/m	−78.52% (below 0%: shrinking)	0.00%	0.00%
EQ Equillium, Inc.	$83.7M	— (loss-making)	— (loss-making)	−52.32% (below 0%: shrinking)	n/m	−38.67% (below 0%: shrinking)	100.00%	0.00%	Compare
NMRA Neumora Therapeutics, Inc.	$80.2M	— (loss-making)	—	—	n/m	+24.45% (above 0%: growing)	0.00%	0.00%	Compare
CLLS Cellectis S.A.	$79.9M	— (loss-making)	—	−62.05% (below 0%: shrinking)	n/m	−36.95% (below 0%: shrinking)	100.00%	(340.69%)	Compare
PMN Promis Neurosciences	$78.0M	— (loss-making)	—	0.00%	n/m	−169.46% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$84.1M	—	—	−26.16%	—	−37.81%	0.00%	0.00%

All 614 Biotechnology stocks →

Corbus Pharmaceuticals Holdings, Inc. (CRBP) key facts

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CRBP traded at $4.52, a market capitalization of $83.8 million.
Return on equity was −54.2% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.